Panelists discuss vaccination, biologics and infection, methotrexate, cardiovascular risk, and serial immunoglobulin testing and imaging
ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
The Patients’ Access to Treatments Act of 2013 would prevent insurance companies from tacking on an additional cost-sharing fee for the specialty medications
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
Treat to Target: Rheumatoid Arthritis in Pregnant Patients
A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
American College of Rheumatology Leads Charge to Address Excessive Patient Cost Sharing
The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.
Managing an In-Office Infusion Practice
The increased utilization of infusible biologics for the treatment of rheumatic diseases has opened the door for you to provide more integrated care for your patients. Having an in-office infusion center gives you the ability to deliver this service to your patients in a familiar and supportive setting.
Drug Updates: EULAR 2012
Tracking the results of drug safety and efficacy
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »